Clinical Trial Update: Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing the combination of ruxolitinib and erlotinib in EGFR-mutant lung adenocarcinoma with acquired resistance to erlotinib has completed re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-01-03